Thomas R. Staab II
2013
In 2013, Thomas R. Staab II earned a total compensation of $1.2M as Senior Vice President and Chief Financial Officer at BioCryst Pharmaceuticals, a 128% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $81,372 |
|---|---|
| Option Awards | $673,965 |
| Salary | $387,486 |
| Stock Awards | $24,140 |
| Other | $12,750 |
| Total | $1,179,713 |
Staab received $674K in option awards, accounting for 57% of the total pay in 2013.
Staab also received $81.4K in non-equity incentive plan, $387.5K in salary, $24.1K in stock awards and $12.8K in other compensation.
Rankings
In 2013, Thomas R. Staab II's compensation ranked 5,913th out of 12,286 executives tracked by ExecPay. In other words, Staab earned more than 51.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,913 out of 12,286 | 52nd |
Division Manufacturing | 2,051 out of 4,612 | 56th |
Major group Chemicals And Allied Products | 599 out of 1,462 | 59th |
Industry group Drugs | 429 out of 1,156 | 63rd |
Industry Biological Products, Except Diagnostic Substances | 65 out of 196 | 67th |
Source: SEC filing on April 11, 2016.
Staab's colleagues
We found four more compensation records of executives who worked with Thomas R. Staab II at BioCryst Pharmaceuticals in 2013.